There was, however, an increased risk of infection in mothers exposed to anti-TNF, similar to that in non-pregnant women; risk of infection did not increase when medication was continued beyond 24 weeks, but discontinuation before Week 24 increased risk of flare [30, 32]. This evidence concerns the gene TNF and infection.